echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Unfortunately, the efficacy of everolimus for pan-cancer patients with mutations in the mTOR signaling pathway is disappointing!

    Clin Cancer Res: Unfortunately, the efficacy of everolimus for pan-cancer patients with mutations in the mTOR signaling pathway is disappointing!

    • Last Update: 2021-07-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    mTOR is a serine-threonine kinase and a key component of a non-overlapping multi-subunit complex with two downstream targets (mTOR complex 1 and 2)


    This is a multi-center, single-group prospective phase II trial to evaluate the therapeutic activity of everolimus, an oral inhibitor of mTORC1, in patients with advanced solid tumors with TSC1/TSC2 or MTOR mutations


    Patients with advanced solid tumors carrying TSC1/TSC2 inactivating mutations or MTOR activating mutations were recruited and treated with 10 mg everolimus every day until the disease progressed or intolerable toxicity appeared


    The type of cancer in the test patient

    The type of cancer in the test patient

    From November 2015 to October 2018, a total of 30 patients were recruited, of which 13 had TSC1 mutations, 15 had TSC2 mutations, 1 had both TSC1 and TSC2 mutations, and 1 had MTOR mutations


    Treatment remission

    Treatment remission

    The median progression-free survival was 2.


    The median progression-free survival was 2.


    Original source:

    Original source:

    Elio Adib, Katarzyna Klonowska, et al.


    Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.